Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference

Andrew Kennedy, Lourens Bester, Riad Salem, Ricky A Sharma, Rowan W Parks, Philippe Ruszniewski, NET-Liver-Metastases Consensus Conference, Andrew Kennedy, Lourens Bester, Riad Salem, Ricky A Sharma, Rowan W Parks, Philippe Ruszniewski, NET-Liver-Metastases Consensus Conference

Abstract

Objectives: Liver metastasis from a neuroendocrine tumour (NET) represents a significant clinical entity. A multidisciplinary group of experts was convened to develop state-of-the-art recommendations for its management.

Methods: Peer-reviewed published reports on intra-arterial therapies for NET hepatic metastases were reviewed and the findings presented to a jury of peers. The therapies reviewed included transarterial embolization (TAE), transarterial chemoembolization (TACE) and radioembolization (RE). Two systems were used to evaluate the level of evidence in each publication: (i) the US National Cancer Institute (NCI) system, and (ii) the GRADE system.

Results: Eighteen publications were reviewed. These comprised 11 reports on TAE or TACE and seven on RE. Four questions posed to the panel were answered and recommendations offered.

Conclusions: Studies of moderate quality support the use of TAE, TACE and RE in hepatic metastases of NETs. The quality and strength of the reports available do not allow any modality to be determined as superior in terms of imaging response, symptomatic response or impact on survival. Radioembolization may have advantages over TAE and TACE because it causes fewer side-effects and requires fewer treatments. Based on current European Neuroendocrine Tumor Society (ENETS) Consensus Guidelines, RE can be substituted for TAE or TACE in patients with either liver-only disease or those with limited extrahepatic metastases.

© 2014 The Authors. HPB published by John Wiley & Sons Ltd on behalf of the International Hepato-Pancreato-Biliary Association.

Figures

Figure 1
Figure 1
Study search strategy and numbers of articles identified
Figure 2
Figure 2
Proposed treatment approach in liver-only metastases from neuroendocrine tumours. LITT, laser-induced thermotherapy; LMs, liver metastases; RE, radioembolization; RFA, radiofrequency ablation; TAE, transarterial embolization; TACE, transarterial chemoembolization; 90Y, yttrium-90

References

    1. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–176.
    1. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8–21.
    1. Yang TX, Chua TC, Morris DL. Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases – a systematic review. Surg Oncol. 2012;21:299–308.
    1. National Cancer Institute. PDQ Levels of Evidence for Adult and Pediatric Cancer Treatment Studies. 2012. Available at (last accessed 1 June 2014)
    1. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ. 2008;336:1049–1051.
    1. de Baere T, Deschamps F, Teriitheau C, Rao P, Conengrapht K, Schlumberger M, et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumours with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol. 2008;19:855–861.
    1. Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumours: a longterm follow-up in 123 patients. Med Oncol. 2011;28(Suppl. 1):286–290.
    1. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumours. Cancer. 1998;83:2293–2301.
    1. Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V, et al. Liver/biliary injuries following chemoembolization of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol. 2012;56:609–617.
    1. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumours: variables affecting response rates and survival. Cancer. 2005;104:1590–1602.
    1. Loewe C, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and longterm results. AJR Am J Roentgenol. 2003;180:1379–1384.
    1. Maire F, Lombard-Bohas C, O'Toole D, Vullierme MP, Rebours V, Couvelard A, et al. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumours: a prospective randomized study. Neuroendocrinology. 2012;96:294–300.
    1. Pitt SC, Knuth J, Keily JM, McDermott JC, Weber SM, Chen H, et al. Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg. 2008;12:1951–1960.
    1. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumours. A prospective phase II study in 24 patients. Cancer. 1993;71:2624–2630.
    1. Ruutiainen AT, Soulen MC, Tuite CM, Clark TW, Mondschein JI, Stavropoulos SW, et al. Chemoembolization and bland embolization of neuroendocrine tumour metastases to the liver. J Vasc Interv Radiol. 2007;18:847–855.
    1. Vogl TJ, Gruber T, Naguib NN, Hammerstingl R, Nour-Eldin NE. Liver metastases of neuroendocrine tumours: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. AJR Am J Roentgenol. 2009;193:941–947.
    1. Cao CQ, Yan TD, Bester L, Liauw W, Morris DL. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg. 2010;97:537–543.
    1. Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271–279.
    1. King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921–929.
    1. Memon K, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Sato KT, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and longterm outcomes. Int J Radiat Oncol Biol Phys. 2012;83:887–894.
    1. Paprottka PM, Hoffmann RT, Haug A, Sommer WH, Raessler F, Trumm CG, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol. 2012;35:334–342.
    1. Rhee TK, Lewandowski RJ, Liu DM, Mulcahy MF, Takahashi G, Hansen PD, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumours: preliminary results from a multi-institutional experience. Ann Surg. 2008;247:1029–1035.
    1. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumour liver metastases: a critical appraisal of 48 cases. Ann Surg. 2010;251:910–916.
    1. Kalinowski M, Dressler M, Konig A, El-Sheik M, Rinke A, Hoffken H, et al. Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumours: a prospective single centre study. Digestion. 2009;79:137–142.
    1. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009;96:175–184.
    1. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumours. Surg Oncol Clin N Am. 2003;12:231–242.
    1. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002;26:985–990.
    1. Eriksson J, Stalberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumours. World J Surg. 2008;32:930–938.
    1. Vogl TJ, Naguib NN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NE. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol. 2009;72:517–528.
    1. Wang LM, Jani AR, Hill EJ, Sharma RA. Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases. J Clin Pathol. 2013;66:205–211.
    1. Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumours. Eur Radiol. 2003;13:136–140.
    1. Dutton S, Kenealy N, Love S, Wasan H, Sharma R, Group FP, et al. Study protocol: FOXFIRE: an open-label, randomized, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional selective internal radiation therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer. 2014;14:497.
    1. Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumours treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2011;52:1361–1368.
    1. Yadegarfar G, Friend L, Jones L, Plum LM, Ardill J, Taal B, et al. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013;108:301–310.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться